Continuing research into COVID-19 is being done worldwide, with some researchers showing concern among the population of vaccinated individuals testing positive for the virus – including concerns about the durability of protection against highly contagious emerging strands. Researchers are still learning more about vaccinations against viruses and diseases in comparison to the body’s natural immune responses (https://ibn.fm/m2630).
“Following our comprehensive profiling of the effects of neutralizing antibodies, T cell immunity and non-neutralizing alternate antibody msabe found correlates of immunity in the context of both complete protection and mitigation of viral burden in breakthrough infection,” a major study’s co-author, Daniel Zhu, stated. “We also observed differences in the robustness of key immune response features across vaccine doses, insights that could help guide future vaccine design and boosting.”
This is where immune system monitoring technologies such as the one developed by the biotech innovation company Aditxt (NASDAQ: ADTX), are already proving useful. Aditxt develops technologies focused on mapping and reprogramming the immune system. These immune mapping technologies were created to provide an individual and personalized immune profile. In the preclinical stage, these immune reprogramming technologies are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies.
Recently, Aditxt announced a multi-year partnership with GRS, an affiliate of Guthy-Renker LLC. The partnership will focus on building awareness and visibility among consumers and healthcare providers for the proprietary AditxtScore(TM) Immune Monitoring Platform. Aditxt plans to work closely with GRS to produce and air AditxtScore(TM) television and online commercials, helping to set the stage for an intended rollout in medical offices, pharmacies, laboratories, and employers nationwide (https://ibn.fm/ogSaT).
“AditxtScore(TM) is the right technology at the right time. Our first application, AditxtScore(TM) for COVID-19, delivers timely reports on vulnerability and immune status to SARS-CoV-2 and its known variants, giving consumers and their physicians the data they need to make informed health decisions for themselves and their families,” Aditxt co-founder and CEO Amro Albanna stated.
Albanna added that the company’s AditxtScore immune monitoring center in Richmond, VA, which is fully operational and is designed to support increased demand for the company’s products and services, also voiced enthusiasm for working with GRS on the production of TV and online spots and marketing campaigns for AditxtScore: “Based on Guthy-Renker’s decades-long track record in direct marketing, GRS has proven that they understand what is required to help build a sustainable brand, and we believe this partnership is a great opportunity to introduce AditxtScore nationally.”
Boris Shimanovsky, President of GRS, also commented on the partnership, underlining that AditxtScore is designed to provide a more detailed profile of the immune system, allowing individuals to understand, manage, and monitor their immunity profiles. “We believe AditxtScore will fundamentally change what we know about immune health, and we’re excited to partner with the Aditxt team and help bring transparency and customer empowerment to an industry requiring both.”
Although still in its early stages, the immune repertoire sequencing market is forecasted to reach a value of $175 million by the end of 2027, registering a CAGR of 7.5% from 2020 to 2027. Growth in the industry is fueled by the advancements in next-generation sequencing, which have birthed the new technology in the form of immune repertoire sequencing, which is receiving widespread acceptance from the pharmacogenomics-based drug industry and the government (https://ibn.fm/pu1z8).
For more information, visit the company’s website at www.Aditxt.com.
NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Scientists have found that keeping circadian rhythms, the variations in body processes during the course…
While many capitalization structures are diluted in the landscape of over-the-counter (“OTC”) markets, Earth Science…
The United States has formally communicated its immediate withdrawal from the World Health Organization (WHO), denying…
Psoriasis is a chronic skin condition that afflicts at least 60 million individuals globally. Nearly 80% of these affected people also…
Researchers at the University of Michigan (U-M) have developed a system that leverages both AI…
LIXTE is developing a first-in-class therapy designed to enhance the effectiveness of existing cancer treatments…